FindTrial
Sign In

Genome sequencing

GENETIC7 trials

Sponsors

British Columbia Cancer Agency, M.D. Anderson Cancer Center, VA Boston Healthcare System, Centre Hospitalier Universitaire Dijon, Brigham and Women's Hospital

Conditions

Advanced CancersCancers That Cannot be Treated With Curative IntentDevelopmental AnomaliesGenetic DiseaseGenetic Predisposition to DiseaseHereditary DiseasesHyperparathyroidismHypoxic Ischemic Encephalopathy

Unknown Phase

Personalized Oncogenomics (POG) Program of British Columbia
RecruitingNCT02155621
British Columbia Cancer AgencyAdvanced Cancers, Cancers That Cannot be Treated With Curative Intent, Metastatic Cancers
Start: 2014-07-31End: 2026-03-31Target: 5000Updated: 2025-09-22
Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
NCT03053999
M.D. Anderson Cancer CenterHyperparathyroidism, Multiple Endocrine Neoplasia, Pancreatic Neuroendocrine Tumors
Start: 2012-10-09End: 2023-10-31Target: 53Updated: 2019-09-12
The VetSeq Study: a Pilot Study of Genome Sequencing in Veteran Care
CompletedNCT03380819
VA Boston Healthcare SystemGenetic Disease, Rare Diseases
Start: 2017-12-29End: 2022-12-31Updated: 2023-04-26
Study of the Diagnostic Value of Rapid High Throughput Genome Sequencing Analysis in Diagnostic Emergency Situations
CompletedNCT03956069
Centre Hospitalier Universitaire DijonDevelopmental Anomalies
Start: 2020-06-23End: 2022-07-25Updated: 2022-09-21
Implementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants
CompletedNCT05161169
Brigham and Women's HospitalGenetic Predisposition to Disease, Hereditary Diseases
Start: 2022-12-21End: 2025-06-30Updated: 2026-03-05
Mechanisms of Type 1 Diabetes Endophenotypes
RecruitingNCT05764850
Pediatric Clinical Research PlatformGenetic Predisposition to Disease, Type 1 Diabetes Mellitus
Start: 2023-02-01End: 2026-02-01Target: 150Updated: 2023-03-13
The HIEnome Study: Genome Sequencing for Perinatal HIE
RecruitingNCT06762795
Baylor College of MedicineHypoxic Ischemic Encephalopathy, Hypoxic Ischemic Encephalopathy (HIE), Hypoxic Ischemic Encephalopathy of Newborn
Start: 2025-05-15End: 2027-06-30Target: 25Updated: 2025-10-01

Related Papers

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration.
2023-03-2420 citations
Abstract B066: Elucidating the role of insulin receptor isoform expression in metastatic pancreatic ductal adenocarcinoma
Cancer Research2022-11-151 citations
Abstract LB129: Analysis of KRAS wildtype pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma
Cancer Research2022-06-15
Molecular characterization of long-term and short-term survivors of advanced pancreatic ductal adenocarcinoma.
Journal of Clinical Oncology2022-06-014 citations
Abstract 630: Response to nivolumab in a pediatric chordoma with overexpression of brachyury
Cancer Research2021-07-011 citations
Beyond <i>BRCA</i>? clinical utility of homologous recombination deficiency in gastrointestinal cancers.
Journal of Clinical Oncology2021-01-20
Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma
Cancer Medicine2020-12-2813 citations
Whole genome and transcriptome analysis and the link between insulin receptor aberration and diabetes in PDAC.
Journal of Clinical Oncology2020-02-01
Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis.
2020-01-061 citations
Afatinib as a novel potential treatment option for <i>NRG1</i> fusion-positive tumors.
Journal of Global Oncology2019-10-076 citations
Comprehensive transcriptome analysis reveals link between epigenetic dysregulation, endogenous retrovirus expression and immunogenicity in metastatic colorectal carcinoma.
Journal of Clinical Oncology2019-05-204 citations
Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.
Journal of Clinical Oncology2019-05-201 citations
Whole genome and transcriptome analysis (WGTA) of metastatic adrenocortical carcinoma (mACC).
Journal of Clinical Oncology2019-05-201 citations
Whole genome and transcriptome analysis (WGTA) of metastatic adrenocortical carcinoma (mACC).
Journal of Clinical Oncology2019-03-013 citations
Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.
Journal of Clinical Oncology2019-01-291 citations
Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.
2017-12-0179 citations
Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing
Molecular Case Studies2017-11-0143 citations
Management of germline findings revealed throughout the course of tumor-normal whole genome sequencing in oncology.
Journal of Clinical Oncology2017-05-20
Abstract B81: Gene expression analysis demonstrates prognostic subtypes in metastatic pancreatic ductal adenocarcinoma (PDAC)
Cancer Research2016-12-141 citations
Comprehensive genomic analysis in metastatic pancreatic ductal adenocarcinoma (PDAC).
Journal of Clinical Oncology2016-02-011 citations